85 studies on Sermorelin curated from PubMed, ClinicalTrials.gov, and EuropePMC. Updated daily.
Independent certificate-of-analysis evidence from third-party labs — the data behind the studies. Updated as new COAs are verified. Read the full grey-market analysis →
| Manufacturer | Batches | Avg purity | |
|---|---|---|---|
| Shanghai Sigma Audley Ssa | 14 | 99.03% | View COA → |
| Qing Li Peptide | 5 | 99.79% | View COA → |
| Modern Research LLC | 5 | 99.43% | View COA → |
| Hk Peptides | 5 | 99.08% | View COA → |
| Zlz Peptide | 4 | 99.61% | View COA → |
| Sry Labs | 4 | 99.26% | View COA → |
| Allen Biotechnology Co Abc | 4 | 99.24% | View COA → |
| PEPTIDES WORLD | 3 | 99.89% | View COA → |
Recent certificates: #14724 (99.5%) · #14725 (99.5%) · #13240 (80.583%) · #14137 (99.874%) · #20260 (99.213%) · #20261 (99.213%)
Manufacturers with published third-party certificates of analysis for Sermorelin. Open a vendor to see every batch we've verified.
The termination of this long-running study highlights the significant challenges inherent in conducting extensive, multi-year clinical research, particularly in broad observational contexts like endocrine diseases. Wh…
Understanding the precise role of GHRH (a hormone that stimulates GH release) in acromegaly is crucial for developing more targeted therapies. If endogenous GHRH significantly contributes to GH hypersecretion, then GH…
If GHRH were found to be effective, this research could pave the way for a novel therapeutic strategy to address age-related sleep disturbances, a widespread issue affecting millions. Successfully augmenting the GH-IG…
The premature termination of this study means a potential avenue for addressing age-related decline in muscle, bone, and fat health through GHRH remains unexplored by this particular trial. If successful, GHRH could h…
These findings suggest that GHRH therapy could represent a novel therapeutic strategy for improving cardiac function and quality of life in older adults with congestive heart failure and reduced growth hormone effect.…
This research is critical for optimizing IVF protocols for a challenging patient population with diminished ovarian reserve, who often have lower success rates with conventional treatments. If the long Clomid protocol…
This study provides compelling evidence that tesamorelin could be a highly effective pharmacological intervention for MASLD, addressing a critical unmet medical need. The significant reduction in liver fat observed su…
The premature termination of this study means a significant opportunity was missed to explore a potential therapeutic avenue for age-related decline. Given the widespread impact of low GH levels on muscle mass, bone d…
The intent behind this study highlights a critical challenge in endocrinology: the potential for significant inter-assay variability to compromise the accurate diagnosis and management of Growth Hormone (GH) disorders…
The intent behind this withdrawn study highlights a critical unmet need: finding effective treatments for sleep-disordered breathing in patients with lipodystrophy. If Tesamorelin could demonstrably improve sleep apne…
These findings, if confirmed upon publication, would establish tesamorelin as a promising therapeutic option for NAFLD in obese individuals, addressing a critical unmet medical need. Given the high prevalence of NAFLD…
Targeting growth hormone pathways with GHRH offers a promising therapeutic strategy for managing abdominal obesity and its associated metabolic risks. If successful, this approach could provide a novel, physiological …
Understanding the sexually dimorphic nature of GH responses to GHRH could profoundly impact the diagnosis and management of Growth Hormone Deficiency. If confirmed, these findings could lead to the development of sex-…
This foundational Phase 1 study is critical because it provides essential data on how Tesamorelin behaves in HIV positive patients, a population with unique metabolic considerations. The successful characterization of…
The potential for Tesamorelin to augment exercise benefits in HIV-positive individuals is highly significant. If successful, this intervention could offer a novel and more effective strategy to combat frailty and phys…
Understanding Tesamorelin's short-term effects in healthy individuals is crucial for broadening its potential therapeutic applications beyond HIV-associated lipodystrophy. If Tesamorelin can safely enhance GH secretio…
The investigation into TH9507, a growth hormone-releasing factor (GRF) analogue, represents an important step in exploring novel therapeutic strategies for Type 2 Diabetes. GRF plays a role in metabolic regulation, an…
This study, had it been completed, could have provided crucial evidence for a novel therapeutic strategy to mitigate cardiovascular risk in individuals with abdominal obesity. By demonstrating a direct link between GH…
Understanding how growth hormone and growth hormone-releasing hormone impact GH secretion and glucose metabolism in HIV-infected patients is profoundly important for managing HIV lipodystrophy and its associated metab…
If the GHRH + Arginine test proves to have high specificity and sensitivity comparable to the ITT, it could represent a significant advancement in diagnosing AGHD. The ITT carries inherent risks due to induced hypogly…
The termination of this study represents a missed opportunity to gain crucial insights into the complex interplay between free fatty acids, obesity, and growth hormone secretion in a vulnerable pediatric population. H…
The withdrawal of this study highlights a persistent gap in research for effective treatments for TBI-related insomnia, a condition that significantly impacts the quality of life for service members and veterans. Had …
This research highlights tesamorelin's potential as a targeted therapeutic option for managing HIV lipodystrophy, offering more than just cosmetic benefits. The significant reduction in visceral fat, coupled with impr…
This Phase 1 study is crucial for establishing the foundational safety and preliminary efficacy signals for VRS-317, a potential long-acting treatment for Growth Hormone Deficiency. If successful in maintaining IGF-I …
The successful development of an oral growth hormone secretagogue like AEZS-130 for diagnostic purposes would represent a significant advancement in the management of Adult Growth Hormone Deficiency (AGHD). Such a tes…
The potential of TH9507 to selectively reduce visceral adipose tissue (VAT) in HIV patients with lipodystrophy is highly significant, as this fat accumulation is strongly linked to serious metabolic complications like…
For women struggling with poor ovarian response (POR), finding effective pre-treatment strategies is paramount to improving the success rates of IVF/ICSI and alleviating the significant emotional and financial burden …
If Growth Hormone Releasing Hormone (GHRH) were to demonstrate positive effects on cognitive function in Mild Cognitive Impairment (MCI), it would offer a novel and promising therapeutic strategy for a condition with …
This research provides crucial insights into the potentiation of GH secretion when GHRH and GHRPs are co-administered, suggesting a more efficient way to stimulate endogenous GH release. The observed synergy could all…
These findings are highly significant as they identify the GHRH receptor as a novel and promising therapeutic target for triple-negative breast cancer, a disease with limited treatment options. The potent anti-prolife…
This research elucidates a critical molecular pathway by which GHRH antagonists like JMR-132 exert their anti-cancer effects, specifically highlighting the essential role of p21/waf1 (a protein that halts cell divisio…
This study highlights a novel therapeutic approach for breast cancer treatment by targeting the GHRH pathway, showing efficacy across both ER+ and ER- subtypes. The ability of MZ-4-71 to inhibit the growth of ER- brea…
These findings are significant as they identify GHRH as a trophic hormone for bronchial neuroendocrine tumors, meaning it actively promotes their growth and activity. This discovery suggests that GHRH receptors could …
This study provides compelling evidence that GHRH antagonists possess significant antiproliferative and pro-apoptotic effects on ovarian cancer cells by targeting the EGFR-Akt signaling pathway. This discovery highlig…
This discovery is significant because it uncovers a novel mechanism by which Growth Hormone Releasing Hormone (GHRH) may exert its diverse biological effects, independent of growth hormone (GH) release. By inducing ni…
This study provides compelling evidence that targeting the GHRH/GH axis with an antagonist can significantly impact multiple facets of aging, including longevity, oxidative stress, and telomerase activity. The observe…
This study provides compelling evidence that GH-RH antagonism can profoundly influence brain function, leading to significant improvements in both cognitive abilities and emotional regulation. These findings suggest a…
This research highlights the therapeutic potential of GHRH antagonists as a novel and targeted approach for treating prostate cancer. By modulating key cellular pathways, specifically restoring the function of the p53…
Given the aggressive nature and poor prognosis of advanced ovarian cancer, identifying new therapeutic avenues is paramount. This research highlights GHRH antagonists as a highly promising novel therapeutic strategy f…
This research highlights the critical protective role of GHRH and the downstream GH/IGF-I axis in mitigating acute liver injury caused by acetaminophen. The findings suggest that maintaining or enhancing GHRH signalin…
This study highlights the complex role of GHRH signaling in cognitive function and its intricate interplay with various neurotransmitter systems. Understanding these pathways could open new avenues for treating cognit…
Free, no account — handy when you're working with Sermorelin.